EyePoint Pharmaceuticals (NASDAQ:EYPT) Releases Earnings Results

EyePoint Pharmaceuticals (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10), Zacks reports. The company had revenue of $11.60 million for the quarter, compared to analysts’ expectations of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.

EyePoint Pharmaceuticals Stock Performance

NASDAQ EYPT opened at $6.58 on Thursday. The stock has a 50-day simple moving average of $7.28 and a 200 day simple moving average of $8.48. EyePoint Pharmaceuticals has a twelve month low of $5.54 and a twelve month high of $26.76. The stock has a market capitalization of $449.09 million, a PE ratio of -3.29 and a beta of 1.51.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Citigroup initiated coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, February 6th. Robert W. Baird decreased their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.